0000000000135944

AUTHOR

Marc Decramer

showing 4 related works from this author

Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use

2013

SummaryBackgroundIndacaterol is a once-daily, long-acting β2-agonist bronchodilator that improves dyspnoea and health status in patients with moderate-to-severe COPD. While its bronchodilator effects have been shown to be maintained in different patient subgroups, effects on clinical outcomes in certain subgroups are not yet defined.MethodsPost-hoc analysis of pooled clinical study data to investigate efficacy and safety of indacaterol compared with placebo and other long-acting bronchodilators (formoterol, salmeterol, open-label tiotropium) in patient subgroups defined by COPD severity (GOLD stage II or III; n = 4082) and ICS use at baseline (no/yes; n = 4088). Efficacy outcomes were troug…

MaleCopd patientsVital CapacityQuinolonesSeverity of Illness IndexPulmonary Disease Chronic ObstructiveForced Expiratory VolumeFormoterol FumarateBronchodilatorFormoterolSalmeterolSalmeterol XinafoateRandomized Controlled Trials as TopicIndacaterolCOPDMiddle AgedBronchodilator AgentsTreatment OutcomeEthanolaminesAnesthesiaIndansDrug Therapy CombinationFemaleSalmeterolmedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classScopolamine DerivativesPlaceboDrug Administration ScheduleInternal medicineAdministration InhalationmedicineHumansCOPDAlbuterolTiotropium BromideAdrenergic beta-2 Receptor AgonistsGlucocorticoidsAgedbusiness.industryTiotropiummedicine.diseaserespiratory tract diseasesDyspneaLong actingIndacaterolFormoterolbusinessRespiratory Medicine
researchProduct

New horizons in early stage COPD--improving knowledge, detection and treatment.

2011

SummaryEarly stage COPD carries a significant healthcare burden that is currently underrecognised, underdiagnosed and undertreated. Furthermore, patients at this stage can rapidly decline to advanced disease, especially if they continue to smoke. The natural history of the disease in early stages remains largely unknown, and emerging evidence indicates that we are able to reduce lung function decline and exacerbations, and improve quality of life, in early stage COPD, mainly through smoking cessation. But new evidence from randomised clinical trials also suggests an impact of pharmacotherapy on clinical outcomes in early disease. Guidelines need to be updated to reflect this greater underst…

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyHealth Knowledge Attitudes Practicemedicine.medical_treatmentDiseasePulmonary Disease Chronic ObstructiveQuality of life (healthcare)PharmacotherapyHealth careDiagnosismedicineCOPDHumansIntensive care medicineCOPDbusiness.industryCase-findingEarly diseasemedicine.diseasePrognosisBronchodilator AgentsClinical trialNatural historyTreatmentEarly DiagnosisSpirometryPractice Guidelines as TopicPhysical therapyQuality of LifeSmoking cessationFemaleSmoking CessationbusinessRespiratory medicine
researchProduct

Determinants of physical activity in daily life in candidates for lung transplantation

2012

BACKGROUND: Participation in daily physical activity (PA) has never been objectively assessed in candidates for lung transplantation (LTx). The main research questions were: 1) How active are LTx-candidates in daily life? 2) What are determinants of activity behavior before LTX? METHODS: Ninety-six candidates for LTx (diagnosis of COPD or interstitial lung disease; mean age 55 ± 7 years) underwent measurements of PA, pulmonary function, 6-min walking distance (6MWD), muscle force and health-status (SF-36 scale). RESULTS: Patients were markedly inactive (5% of waking hours walking, 26% standing and 69% sedentary). Backward multiple regression identified 6MWD (expressed as % of predicted valu…

AdultMaleQuality of lifePulmonary and Respiratory Medicinemedicine.medical_specialtyActivities of daily livingCross-sectional studymedicine.medical_treatmentPhysical activityMEDLINEWalkingMotor ActivityPulmonary Disease Chronic ObstructiveQuality of life (healthcare)Forced Expiratory VolumeActivities of Daily LivingmedicineExercise capacityHumansLung transplantationbusiness.industryPhysical activityMuscle strengthMiddle Agedrespiratory systemExercise capacitymedicine.diseaseRespiratory MusclesCross-Sectional StudiesLung transplantationMood disordersPreoperative PeriodRespiratory MechanicsPhysical therapyMood disordersFemaleSeasonsHuman medicineLung Diseases InterstitialbusinessRespiratory Medicine
researchProduct

Physical inactivity in patients with COPD, a controlled multi-center pilot-study

2010

Physical activity (PA) has been reported to be reduced in severe chronic obstructive pulmonary disease (COPD). Studies in moderate COPD are currently scarce. The aim of the present study was to investigate physical activity in daily life in patients with COPD (n=70) and controls (n=30).A multi-center controlled study was conducted. PA was assessed using a multisensor armband device (SenseWear, BodyMedia, Pittsburgh, PA) and is reported as the average number of steps per day, and the time spent in mild and moderate physical activity.Patients suffered from mild (n=9), moderate (n=28), severe (n=23) and very severe (n=10) COPD. The time spent in activities with mild (80 + or - 69 min vs 160 + …

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyActivities of daily livingPilot ProjectsSettore MED/10 - Malattie Dell'Apparato RespiratorioMotor ActivitySeverity of Illness IndexArticlePulmonary Disease Chronic ObstructiveForced Expiratory VolumeSeverity of illnessActivities of Daily LivingMedicineCOPDHumansIn patientCOPD Physical activityAgedCOPDAnalysis of Variancebusiness.industryPhysical activityDisease progressionRespiratory diseaseCase-control studyStepsMiddle Agedmedicine.diseaseActivity monitorItalyCase-Control StudiesPhysical therapyDisease ProgressionExercise TestEnergy expenditureFemaleAnalysis of variancebusiness
researchProduct